Limitations
ABM, depressive symptoms, diagnosable disorder, MDD, depression
MACLEOD
Measures of depressive symptoms should ideally also include a clinician-rated scale (Uher et al., Despite the randomization procedure there was a difference in depressive symptoms at baseline which was clinically meaningful (3.2 BDI-II points). Moreover, current MDD was more prevalent in the ABM group. The therapeutic effect of ABM might be dependent on depression severity and the presence of a diagnosable disorder (Baert, De Raedt, Schacht, & Koster, The lack of an assessment-only condition limits interferences of the added benefit of taking part in a structured daily cognitive activity beyond the natural course of depressive symptoms. Moreover, the closely matched control condition of the present trial might be better apt at delineating mechanism in basic research than investigating the effectiveness of ABM in clinical setting (Blackwell, Woud, & MacLeod, 